Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 May;32(5):755–757. doi: 10.1128/aac.32.5.755

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

F G Araujo 1, D R Guptill 1, J S Remington 1
PMCID: PMC172266  PMID: 2840017

Abstract

Doses of 200 mg of azithromycin per kg (body weight) administered by the oral route daily for 10 days completely protected mice against death caused by intraperitoneal infection with Toxoplasma gondii. The same treatment regimen also protected 80% of mice infected intracerebrally, which suggests that azithromycin attains active concentrations in the inflamed central nervous system.

Full text

PDF
755

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Remington J. S. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother. 1974 Jun;5(6):647–651. doi: 10.1128/aac.5.6.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Remington J. S. Toxoplasmosis in immunocompromised patients. Eur J Clin Microbiol. 1987 Feb;6(1):1–2. doi: 10.1007/BF02097180. [DOI] [PubMed] [Google Scholar]
  3. Chan J., Luft B. J. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrob Agents Chemother. 1986 Aug;30(2):323–324. doi: 10.1128/aac.30.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chang H. R., Pechere J. C. Effect of roxithromycin on acute toxoplasmosis in mice. Antimicrob Agents Chemother. 1987 Jul;31(7):1147–1149. doi: 10.1128/aac.31.7.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Garin J. P., Pellerat J., Maillard, Woehrle R., Hezez Bases théoriques de la prévention par la spiramycine de la toxoplasmose congénitale chez la femme enceinte. Presse Med. 1968 Dec 7;76(48):2266–2266. [PubMed] [Google Scholar]
  6. Hitchings G. H., Burchall J. J. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv Enzymol Relat Areas Mol Biol. 1965;27:417–468. doi: 10.1002/9780470122723.ch9. [DOI] [PubMed] [Google Scholar]
  7. Hofflin J. M., Conley F. K., Remington J. S. Murine model of intracerebral toxoplasmosis. J Infect Dis. 1987 Mar;155(3):550–557. doi: 10.1093/infdis/155.3.550. [DOI] [PubMed] [Google Scholar]
  8. Ruskin J., Remington J. S. Toxoplasmosis in the compromised host. Ann Intern Med. 1976 Feb;84(2):193–199. doi: 10.7326/0003-4819-84-2-193. [DOI] [PubMed] [Google Scholar]
  9. Walsh M., Kappus E. W., Quinn T. C. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 May;31(5):811–812. doi: 10.1128/aac.31.5.811. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES